Drugs / LSALT Peptide
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04402957 | Oct 2020 → May 2021 | COVID-19, acute kidney injury, acute respiratory distress syndrome, severe acute respiratory syndrome | Arch Biopartners Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04330690 | Mar 2020 → Mar 2024 | COVID-19 | Sunnybrook Health Sciences Centre | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LSALT Peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04330690 ↗ |
| Known as | Metablok | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314991 ↗ |
| Action | Inhibit | “through the direct inhibition of leukocyte adhesion to DPEP-1” NCT04402957 ↗ |
| Modality | Peptide | “LSALT, a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH” NCT04402957 ↗ |
| Route | Intravenous | “5 mg , 2 hour IV infusion once daily for up to 14 consecutive days” NCT04330690 ↗ |
| Target | DPEP1 | “binds to dipeptidase-1 (DPEP-1)” NCT04402957 ↗ |